Voyager Therapeutics, Inc.
NASDAQ:VYGRBiotechnology
+$0.09 today
- Market cap
- $94.59M
- Beta
- 1.25
- P/E (TTM)
- -1.9
- EPS (TTM)
- -$1.96
Volume 0.99M
Average 0.54M
Returns on capital
Voyager Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-61.1%
avg -44.6%
ROIC
-56.4%
avg -26.4%
ROA
-47.5%
avg -19.3%
Analysis
ROA is currently the strongest return metric at -47.5% versus its period average of -19.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Alfred W. Sandrock Jr. | CEO & Director | USD 1.05M | 68 | — | — |
Robin Swartz | President | USD 738.95K | 56 | 267.99K | 0.44% |
Krystof Bankiewicz | Founder | — | — | — | — |
Mathieu Nonnenmacher | Vice President of Gene Therapy | — | — | — | — |
Mihalis Kariolis | Vice President of Non-Viral Therapeutics | — | — | — | — |
Todd Carter | Chief Scientific Officer | — | 56 | — | — |
Amy Quinlan | Principal Accounting Officer | — | 51 | 28.50K | 0.05% |
Trista Morrison | Chief Corporate Affairs Officer & Chief of Staff to the Chief Executive Officer | — | 49 | — | — |
Mark A. Kay | Founder | — | 68 | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 1, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
11
$297,956.76
Net Transaction Value
−$297,956.76
Net selling
Most Active
Sandrock Alfred
4 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Apr 2, 26Apr 2, 2026 | Sandrock Alfred Direct | Sell | $44.5K$44,547.57 |
| Feb 24, 26Feb 24, 2026 | Swartz Robin Direct | Sell | $24.3K$24,346.66 |
| Feb 24, 26Feb 24, 2026 | Sandrock Alfred Direct | Sell | $53.8K$53,806.63 |
| Feb 24, 26Feb 24, 2026 | Jorgensen Nathan D. Direct | Sell | $17.6K$17,598.36 |
| Feb 24, 26Feb 24, 2026 | Carter Todd Alfred Direct | Sell | $15.7K$15,694.24 |
| Feb 18, 26Feb 18, 2026 | Swartz Robin Direct | Sell | $13.4K$13,354.08 |
| Feb 18, 26Feb 18, 2026 | Carter Todd Alfred Direct | Sell | $11.4K$11,355.44 |
| Feb 18, 26Feb 18, 2026 | Sandrock Alfred Direct | Sell | $40K$40,006.12 |
| Feb 10, 26Feb 10, 2026 | Swartz Robin Direct | Sell | $17.6K$17,590.65 |
| Feb 10, 26Feb 10, 2026 | Sandrock Alfred Direct | Sell | $46.1K$46,085.76 |
1–10 of 11
Summary
Insiders reported 0 buys worth $0.00 and 11 sells worth $297,956.76 over the last 12 months. That adds up to net selling of $297,956.76. Sandrock Alfred was the most active insider with 4 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | -0.4% | +15.1% (5yr)4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Recent growth has been strongest in Revenue at -0.4% over three years. Forward estimates point to Revenue at +15.1% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Voyager Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about VYGR's management, answered from reported figures.
Who manages VYGR?
Voyager Therapeutics, Inc. (VYGR) lists 9 active executives. The top listed executive is Alfred W. Sandrock Jr., CEO & Director.
Are VYGR insiders buying or selling?
Recent insider activity shows net buying of $53.52M.
Continue the stock analysis
Jump to another research area for this company.